Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.60 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.54 |
| ▸ | BHMT | Q93088 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091655 | 1.00 | PTGS1 (0.60) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL6926435 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL11866992 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL2091575 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL1158162 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL17075565 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL2091563 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL17075566 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL6927655 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT | |
| SCHEMBL11870393 | 0.99 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024050176-A1 | INJECTABLE METHODS TO TREAT DEFICIENCIES IN GLUTATHIONE METABOLISM AND HOMOCYSTINURIA | RUBIN DARREN ALEXANDER (US) | 2024-03-07 | — | — | WO | claimed |
| US-20240065995-A1 | INJECTABLE METHODS TO TREAT DEFICIENCIES IN GLUTATHIONE METABOLISM AND HOMOCYSTINURIA | RUBIN DARREN ALEXANDER (US) | 2024-02-29 | — | — | US | claimed |
| US-20160228489-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF DEGENERATIVE SKIN DISORDERS ESPECIALLY CAUSED BY IONIZING RADIATIONS | SOLOSALE S.R.L. (IT) | 2016-08-11 | — | — | US | claimed |
| EP-2775874-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF DEGENERATIVE SKIN DISORDERS ESPECIALLY CAUSED BY IONIZING RADIATIONS | Solosale S.r.l. (IT) | 2014-09-17 | — | — | EP | claimed |
| WO-2013068964-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF DEGENERATIVE SKIN DISORDERS ESPECIALLY CAUSED BY IONIZING RADIATIONS | SOLOSALE S.R.L. (IT) | 2013-05-16 | — | — | WO | claimed |
| EP-0536231-B1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES AND COMPOUNDS OBTAINED FROM SAID PROCESS | BOEHRINGER MANNHEIM ITALIA (IT) | 1996-10-23 | — | — | EP | claimed |
| US-5382679-A | Process for the preparation of glutathione S-acyl derivatives, compounds obtained from said process and an intermediate useful for the preparation thereof | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1995-01-17 | — | — | US | claimed |
| EP-0536231-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF. | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-04-14 | — | — | EP | claimed |
| WO-1992000320-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-01-09 | — | — | WO | claimed |
| WO-2024050176-A1 | INJECTABLE METHODS TO TREAT DEFICIENCIES IN GLUTATHIONE METABOLISM AND HOMOCYSTINURIA | RUBIN DARREN ALEXANDER (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240065995-A1 | INJECTABLE METHODS TO TREAT DEFICIENCIES IN GLUTATHIONE METABOLISM AND HOMOCYSTINURIA | RUBIN DARREN ALEXANDER (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2023119167-A1 | PHARMACEUTICAL COMPOSITION BASED ON GLUTATHIONE THIOESTER AND OLEUROPEIN FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | INNBIOTEC PHARMA S.R.L. (IT) | 2023-06-29 | — | — | WO | disclosed |
| US-20180256681-A1 | PROTECTION AGAINST AND TREATMENT OF IONIZING RADIATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-09-13 | — | — | US | disclosed |
| US-9895413-B2 | Protection against and treatment of ionizing radiation | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-20 | — | — | US | disclosed |
| US-5472698-A | Mixture of (N-acetyl)-L-serine, N-acetylcysteine and alpha-lipoic acid which promotes ceramide production in skin cells | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| US-5382679-A | Process for the preparation of glutathione S-acyl derivatives, compounds obtained from said process and an intermediate useful for the preparation thereof | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1995-01-17 | — | — | US | disclosed |
| EP-0536231-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF. | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-04-14 | — | — | EP | disclosed |
| EP-0514451-A1 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. | UNIV TEXAS (US) | 1992-11-25 | — | — | EP | disclosed |
| WO-1992000320-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991011117-A2 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228489-A1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF DEGENERATIVE SKIN DISORDERS ESPECIALLY CAUSED BY IONIZING RADIATIONS | GSTA2, GSTO1, GSTA1 | PTGS1 170/4885GSTK1 5/4885GLO1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.